Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial - European Medical Journal
×

Browse

Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial

|
Oncology

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews what is known about the functions of poly (ADP-ribose) polymerase (PARP) and outlines the rational development of PARP inhibitors as anticancer agents for tumours associated with BRCA gene mutations. Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.

This programme is supported by BioMarin Pharmaceutical.